Advance preferences regarding thrombolysis in patients at risk for stroke: a cross-sectional study: Table 1

Flatharta, Tomás Ó; Khan, Asim Ali; Walsh, T. N.; O’Donnell, Martin J.; O'Keefe, Sophie

doi:10.1093/qjmed/hcu142

Cited by 3 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients who suffer ischemic stroke or who are consulted based on a theoretical scenario will generally accept the risks of fatal or symptomatic ICH, to obtain the potential benefits of functional independence and an excellent outcome. 34 Ask your older loved ones what they would want.…”

Section: Summary Of the Evidencementioning

confidence: 99%

CJEM Debate Series: #TPA should be the initial treatment in eligible patients presenting with an acute ischemic stroke

Milne

Lang

Ting

et al. 2020

CJEM

View full text Add to dashboard Cite

Section: Summary Of the Evidencementioning

confidence: 99%

CJEM Debate Series: #TPA should be the initial treatment in eligible patients presenting with an acute ischemic stroke

Milne

Lang

Ting

et al. 2020

CJEM

View full text Add to dashboard Cite

“…The difficulties in obtaining informed consent for IVT have been the subject of a number publications 37,39‐61 . Not even under the ideal circumstances of a randomised study can the process of informed consent be carried out in an unproblematic way 47 .…”

Section: Figurementioning

confidence: 99%

Ethical issues in stroke thrombolysis revisited

Appelros

Svensson

Heidenreich

et al. 2021

Acta Neuro Scandinavica

View full text Add to dashboard Cite

Ethical issues in stroke thrombolysis revisitedBack in 1997, a bioethical paper on intravenous thrombolysis in acute ischaemic stroke (IVT), authored by Anthony J. Furlan and George Kanoti, was published. 1 Based on the criteria modified from Schwartz 2 (safety, efficacy, effectiveness, efficiency and outcome), the authors found several ethical problems that were associated with IVT. They can be summarised as a weak proportionality between positive and negative outcomes, and a lack of relation to patient preferences.The literature on IVT has continued to grow after 1997. Most randomised studies on alteplase were published after that, and the debate on IVT has continued to be lively, even over the last decade. [3][4][5][6][7][8][9] Time has therefore come to revisit the ethical issues raised in 1997. The purpose of this paper is to analyse whether these issues have been resolved. More specifically, the following issues will be reviewed as follows:1. Lack of standardisation of outcome endpoints.2. A poorly substantiated beneficial effect.3. Unsolved safety problems, that is an increased risk of intracranial haemorrhage and death.4. Uncertainties regarding patient preferences. Difficulties in obtaining informed consent.As alteplase is the most studied thrombolytic drug, 10 we will solely deal with this drug. Each section will be commence with a

show abstract

Coordinating Options for Acute Stroke Therapy (COAST): An Advance Directive for Stroke

Spokoyny

Cederquist

Clay

et al. 2015

The Journal of Clinical Ethics

View full text Add to dashboard Cite

Advance preferences regarding thrombolysis in patients at risk for stroke: a cross-sectional study: Table 1

Abstract: Advance discussion of the potential risks and benefits of thrombolysis in at-risk patients may improve decision making if thrombolysis is being considered and the patient can no longer make a decision.

Cited by 3 publications

References 23 publications

CJEM Debate Series: #TPA should be the initial treatment in eligible patients presenting with an acute ischemic stroke

CJEM Debate Series: #TPA should be the initial treatment in eligible patients presenting with an acute ischemic stroke

Ethical issues in stroke thrombolysis revisited

Coordinating Options for Acute Stroke Therapy (COAST): An Advance Directive for Stroke

Contact Info

Product

Resources

About